Literature DB >> 1115441

Vitamin D intoxication in an anephric child.

S J Counts, D J Baylink, F H Shen, D J Sherrard, R O Hickman.   

Abstract

Although the biologically active metabolite of vitamin D, 1,25-dihydroxycholecalciferol, is synthesized exclusively by kidney tissue, severe hypercalcemia developed in an anephric child treated with large doses of vitamin D. Treatment by calcium-free peritoneal dialysis acutely reduced serum calcium from 17.2 to 14.2 mg/100 ml. This decrement was effected by removal of three times the total calcium in extracellular fluid, suggesting enhanced bone resorption. Oral prednisolone for 7 days reduced serum calcium to 13 mg/100 ml, but hypercalcemia recurred rapidly after prednisolone was stopped. Calcitonin, given for only 4 one-half days, produced normocalcemia. Maximum serum 25-hydroxyvitamin D (25-OHD), observed immediately after vitamin D was stopped, was 635 ng/ml (normal range 23-32 ng/ml) and subsequently decreased with an initial half-time of 10 days. Losses in peritoneal dialysate may have contributed to disappearance of serum 25-OHD. Because of the high serum levels of 25-OHD and absence of renal tissue, 25-OHD was the likely metabolite that caused hypercalcemia, probably by stimulation of bone resorption, though contribution to hypercalcemia by another vitamin D metabolite cannot be absolutely excluded.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1115441     DOI: 10.7326/0003-4819-82-2-196

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

Review 1.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

2.  Serum 25-hydroxy vitamin D in normal and osteomalacic subjects: a comparison of two assay techniques.

Authors:  B Murray; R Freaney
Journal:  Ir J Med Sci       Date:  1979-01       Impact factor: 1.568

3.  Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.

Authors:  M R Hughes; D J Baylink; P G Jones; M R Haussler
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

4.  Effect of calcitonin and vitamin D in osteoporosis.

Authors:  G M Palmieri; J A Pitcock; P Brown; J G Karas; L J Roen
Journal:  Calcif Tissue Int       Date:  1989-09       Impact factor: 4.333

5.  25-Hydroxyvitamin D levels in patients treated with high-dosage ergo- and cholecalciferol.

Authors:  J M Gertner; M Domenech
Journal:  J Clin Pathol       Date:  1977-02       Impact factor: 3.411

6.  25-hydroxy-vitamin D levels in a patient with hypervitaminosis D.

Authors:  H v Lilienfeld-Toal; W Messerschmidt; B Sturm; H Ochs
Journal:  Klin Wochenschr       Date:  1978-07-15

Review 7.  Vitamin D: deficiency, sufficiency and toxicity.

Authors:  Fahad Alshahrani; Naji Aljohani
Journal:  Nutrients       Date:  2013-09-13       Impact factor: 5.717

Review 8.  Systematic review of the toxicity of short-course oral corticosteroids in children.

Authors:  Fahad Aljebab; Imti Choonara; Sharon Conroy
Journal:  Arch Dis Child       Date:  2016-01-14       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.